Document is current
Any future updates will be listed below
-
Authors
Parravano, Mariacristina https://orcid.org/0000-0002-2223-7311
Fragiotta, Serena https://orcid.org/0000-0002-6214-6270
Costanzo, Eliana https://orcid.org/0000-0002-9916-8895
Giannini, Daniela https://orcid.org/0000-0001-5704-3931
De Geronimo, Daniele https://orcid.org/0000-0003-3242-8020
Viggiano, Pasquale https://orcid.org/0000-0002-0323-967X
Riccardo, Sacconi https://orcid.org/0000-0003-2891-2012
Querques, Giuseppe https://orcid.org/0000-0002-3292-9581
- License Information
-
More Information
Article History
Received: 1 November 2021
Revised: 7 November 2021
Accepted: 11 November 2021
First Online: 24 November 2021
Competing interests
: The authors have no competing interests regarding the publication of this study. MP reports personal fees from Allergan, Novartis, Bayer, Zeiss, Omikron, Alfaintes, Sifi outside the submitted work. PV, EC, DG, SF, DDG has nothing to disclose. SR reported personal fees from: Novartis, Bayer, Zeiss outside the submitted work. GQ: Alimera Sciences, Inc.: Consultant/Advisor; Allegro: Advisor; Allergan: Consultant/Advisor; Apellis: Consultant/Advisor; Baush & Lomb: Consultant; Bayer Healthcare Pharmaceuticals: Consultant/Advisor; Boehringer Ingelheim: Advisor; CenterVue: Consultant/Advisor; Heidelberg Engineering: Consultant/Advisor; Lumithera: Advisor; Nevacar: Advisor; Novartis Pharmaceuticals Corporation: Consultant/Advisor; Roche: Consultant/Advisor. SIFI: Advisor/Consultant; Sooft/Fidia: Consultant; Topcon: Consultant; Thea: Consultant; Zeiss: Consultant/Advisor.
